The present invention relates to solid dispersion pharmaceutical. compositions comprising Eslicarbazepine or its pharmaceutically acceptable salts, esters, solvates, polymorphs, enantiomers or mixtures thereof. The present invention also relates to a process for preparing such solid oral pharmaceutical composition comprising Eslicarbazepine acetate and at least one pharmaceutically acceptable excipient and/or carrier. The prior art highlights challenges of Eslicarbazepine during formulation development with convention granulation techniques. Compositions ofEslicarbazepine acetate prepared as per present invention, exhibited desirable formulation technical attributes.
